Details of Disease

General Information of Disease (ID: DISPAKGA)

• Disease Name: Respiratory distress syndrome
• Synonyms: hyaline Membrane disease; RDS - infants; respiratory distress syndrome, infant; hyaline Membrane disease, formerly; NRDS; IRDS; infantile respiratory distress syndrome; RDS; respiratory distress syndrome; respiratory distress syndrome in premature infants; Respiratory Distress Syndrome, Infant; RDS of prematurity
• Disease Class: CB00: Acute respiratory distress syndrome
• Definition: Infant acute respiratory distress syndrome is a lung disorder that affects premature infants caused by developmental insufficiency of surfactant production and structural immaturity of the lungs. The symptoms usually appear shortly after birth and may include tachypnea, tachycardia, chest wall retractions (recession), expiratory grunting, nasal flaring and cyanosis during breathing efforts.
• Disease Hierarchy:
  DISI3C6F: Respiratory distress syndrome of newborn
  DISPAKGA: Respiratory distress syndrome
• ICD Code:
  ICD-11: ICD-11: CB00
  ICD-10: ICD-10: J80
  ICD-9: ICD-9: 518.5, 518.82
  Expand ICD-9: 518.5,518.82
• Disease Identifiers:
  MONDO ID: MONDO_0009971
  MESH ID: C566881
  UMLS CUI: C1968593
  OMIM ID: 267450
  MedGen ID: 368840
  Orphanet ID: 70587

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 5 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Colfosceril palmitate	DML31XY	Approved	Small molecular drug	[1]
Lucinactant	DMOFFAR	Approved	NA	[2]
Picrotoxin	DMIBNG2	Approved	Small molecular drug	[3]
Poractant alfa	DMJFAZO	Approved	NA	[1]
Surfactant ta	DMGLOHV	Approved	NA	[1]

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
HL-10	DMO7TSQ	Phase 3	NA	[4]
Aerosurf	DM2C7S5	Phase 2	Small molecular drug	[5]
BAY1097761	DMCM5Z1	Phase 2	NA	[6]
Pneumostem	DM9NJXX	Phase 2	NA	[7]

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ALS-886	DM7LDX8	Terminated	NA	[8]
TLC-C-53	DMOV2WW	Terminated	NA	[9]

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ACS-6	DM9CFH1	Investigative	Small molecular drug	[10]
PYC-38	DMSFTND	Investigative	NA	[10]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4051).
• [4] ClinicalTrials.gov (NCT00742482) Efficacy and Safety of 3 Doses of HL10 Given at Fixed Time Intervals Compared to Standard Therapy. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT04264156) A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks GA. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT04417036) Safety and Efficacy of Inhaled Pegylated Adrenomedullin (PEG-ADM) in Patients Suffering From Acute Respiratory Distress Syndrome (ARDS): a Double-blind, Randomized, Placebo-controlled, Multicenter Phase 2a/b Clinical Trial. U.S.National Institutes of Health.
• [7] ClinicalTrials.gov (NCT01897987) Follow-up Safety and Efficacy Evaluation on Subjects Who Completed PNEUMOSTEM Phase-II Clinical Trial. U.S. National Institutes of Health.
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017839)
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004234)
• [10] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.